Nathalie D. McKenzie

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

Assessing the acceptability of self-sampling for HPV among Haitian immigrant women: CBPR in action

Lindley A. Barbee, Erin Kobetz, Janelle Menard et al. · Cancer Causes & Control · 2009 · 109 citations

Medicine, Community Health, Preventive Medicine +8

Early outcomes of coronary artery bypass with and without cardiopulmonary bypass in octogenarians

A. Dave Nagpal, Gopal Bhatnagar, Charles Cutrara et al. · Canadian Journal of Cardiology · 2006 · 39 citations

Medicine, Cardiology, Surgery +16

Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Robert W. Holloway, Alberto A. Mendivil, James E. Kendrick et al. · JAMA Oncology · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +14